Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma |
| |
| Institution: | 1. Department of Chemistry, University of Athens, Athens;2. Internal Medicine of Attikon University Hospital, Athens;3. Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece;4. Department of Cellular and Tissue Biopathology of Tumors, University of Montpellier, Montpellier, France;5. Department of Cranio-, Maxillofacial and Oral Surgery, Medical University of Vienna, Wien, Austria;6. Department of Surgery, Yale University School of Medicine, New Haven, USA |
| |
| Abstract: | BackgroundSuccessful application of programmed death 1 (PD1) checkpoint inhibitors in the clinic may ultimately benefit from appropriate patient selection based upon predictive biomarkers. Molecular characterization of circulating tumor cells (CTC) is crucial for the investigation of molecular-targeted therapies while predictive biomarkers for response to PD1 checkpoint inhibitors are lacking. We sought to assess whether overexpression of PD-L1 in CTCs could be detected at baseline and at different timepoints during treatment in a prospective cohort of head and neck squamous cell carcinoma (HNSCC) patients and used to predict clinical outcome after treatment with curative intent.Patients and methodsWe developed a highly sensitive, specific and robust RT-qPCR assay for PD-L1 mRNA expression in EpCAM(+) CTCs. In a prospective cohort of 113 locally advanced HNSCC patients treated with curative intent we evaluated PD-L1 expression in the EpCAM(+) CTC fraction at baseline, after 2 cycles of induction chemotherapy (week 6) and at the end of concurrent chemoradiotherapy (week 15).ResultsPD-L1 overexpression was found in 24/94 (25.5%) patients at baseline, 8/34 (23.5%) after induction chemotherapy and 12/54 (22.2%) patients at the end of treatment. Patients with CTCs overexpressing PD-L1 at end of treatment had shorter progression-free survival (P = 0.001) and overall survival (P < 0.001). Multivariate analysis revealed that PD-L1 overexpression at end of treatment was independent prognostic factor for progression-free survival and overall survival. The absence of PD-L1 overexpression at the end of treatment was strongly associated with complete response with an odds ratio = 16.00 (95% CI = 2.76–92.72, P = 0.002).ConclusionsWe demonstrate that detection of CTCs overexpressing PD-L1 is feasible and may provide important prognostic information in HNSCC. Our results suggest that adjuvant PD1 inhibitors deserve evaluation in HNSCC patients in whom PD-L1(+) CTCs are detected at the end of curative treatment. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
